Novartis Sandoz Prepares For Public Debut With Strong Sales Record And Plans for New Biologic Drugs
Portfolio Pulse from Vandana Singh
Novartis AG has confirmed its plans for a 100% spin-off of the Sandoz business after shareholders approved it. Key regulatory approvals have been obtained, including the approval for listing the Sandoz shares on the SIX Swiss Exchange. Sandoz ADRs are expected to be traded on the OTCQX. Sandoz has secured debt financing of $3.75 billion and plans to introduce at least five additional biologic drugs. Sandoz reported sales of $9.1 billion in 2022 and expects net sales to grow in the mid-single digits through 2028.
September 25, 2023 | 2:38 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Novartis is spinning off Sandoz, which has strong sales records and plans for new biologic drugs. This could potentially impact Novartis' stock in the short term.
The spin-off of Sandoz could have various impacts on Novartis. On one hand, it could free up resources and allow Novartis to focus on its core businesses. On the other hand, it could also lead to a loss of revenue from the Sandoz business. The impact on the stock price will depend on how investors perceive these changes.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100